Is ARWR a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Arrowhead Pharmaceuticals (ARWR) rests on REDEMPLO (plozasiran) launch and label expansion: Plozasiran is now approved for FCS in the U.S., China, Canada, Australia, and the EU, giving Arrowhead its first commercial product. Revenue (FY2025, ended Sept 2025) is ~$829M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. Whether ARWR is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Arrowhead Pharmaceuticals is a biopharmaceutical company built around RNA interference (RNAi), using its TRiM (Targeted RNAi Molecule) platform to design small interfering RNA (siRNA) medicines that silence disease-causing genes in the liver and, increasingly, in tissues like the lung and muscle. Its lead drug, plozasiran (marketed as REDEMPLO), targets APOC3 to lower triglycerides and was approved by the U.S. FDA in November 2025 for familial chylomicronemia syndrome (FCS), with additional approvals in China, Canada, Australia, and the European Union. Behind it sits a broad pipeline spanning cardiometabolic disease, obesity, pulmonary, CNS, and muscle targets, several of which are partnered. The investment picture is defined by large partnerships and lumpy, milestone-heavy revenue rather than steady product sales. A 2024-2025 global license and collaboration agreement with Sarepta Therapeutics brought roughly ~$825M in upfront value (about ~$500M cash plus ~$325M equity) and has since triggered nine-figure milestone payments, while Amgen (olpasiran for Lp(a)) and Novartis are additional partners. Those deals, plus capital raises, left Arrowhead with over ~$1.7B in cash resources as of early 2026, funding a long runway. Because much of the reported revenue is deal-driven, quarterly results swing sharply, and investors weigh the emerging REDEMPLO launch and late-stage readouts against continued operating losses in non-milestone quarters.
What's the case for buying ARWR?
1. REDEMPLO (plozasiran) launch and label expansion
Plozasiran is now approved for FCS in the U.S., China, Canada, Australia, and the EU, giving Arrowhead its first commercial product. The larger commercial opportunity would come from broader indications like severe hypertriglyceridemia, where the addressable patient population is far bigger than the rare FCS setting.
2. Partnership economics
The Sarepta collaboration delivered roughly ~$825M in upfront value and has generated additional milestone payments (including ~$100M and ~$200M tranches reported in late 2025). Amgen's olpasiran and other partnered programs add royalty and milestone potential without Arrowhead bearing all the development cost, though the timing of these payments is uneven.
3. Broad RNAi pipeline beyond the liver
Arrowhead's TRiM platform extends siRNA delivery beyond hepatic targets toward lung, muscle, and CNS tissues, supporting candidates in cardiometabolic disease, obesity (such as ARO-INHBE), and pulmonary conditions. A deep, diversified pipeline gives multiple shots on goal but also spreads capital and clinical risk across many programs.
4. Strong balance sheet and runway
Following partner payments and equity offerings, Arrowhead reported total cash resources of roughly ~$1.78B in early 2026. That funding reduces near-term dilution pressure and lets the company advance late-stage trials and the REDEMPLO commercial build-out without immediate financing risk.
What are the risks to ARWR?
Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. The commercial uptake of REDEMPLO in the small FCS population is unproven, and broader label expansion depends on clinical and regulatory outcomes that can fail or slip. Competition in RNAi and lipid-lowering is intense from larger, better-capitalized rivals. Clinical trial setbacks, safety findings, regulatory delays, and partner decisions (including a partner pausing or returning a program) could all materially affect the stock, which is volatile like most clinical-stage biotech.
How is ARWR valued? (as of JULY 2026)
Snapshot for ARWR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2025, ended Sept 2025): ~$829M
- Q1 FY2026 revenue (Oct-Dec 2025): ~$264M
- Q2 FY2026 revenue (Jan-Mar 2026): ~$74M
- Total cash resources (early 2026): ~$1.78B
- Sarepta deal upfront value: ~$825M (~$500M cash + ~$325M equity)
- Profitability: Milestone quarters profitable; loss-making without milestones
Arrowhead's reported revenue is dominated by partnership and milestone payments, which makes results swing dramatically between quarters (a large Q1 FY2026 milestone quarter versus a much smaller Q2). Traditional valuation multiples are of limited use for a company at this stage, so investors tend to focus on the REDEMPLO launch trajectory, pipeline readouts, cash runway, and deal flow rather than trailing earnings.
How do you decide if ARWR is a buy?
Rather than asking whether ARWR is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ARWR indirectly through an index or sector ETF before adding more.
For the full picture, see the ARWR stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ARWR against your real portfolio and see your actual exposure before deciding.
The bottom line on ARWR
The bottom line: Arrowhead Pharmaceuticals's story right now is REDEMPLO (plozasiran) launch and label expansion, with revenue (fy2025, ended sept 2025) at ~$829M. If you believe that narrative continues, the call is about sizing ARWR sensibly and checking overlap with what you own; if you doubt it (the risk: arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ARWR with Walnut
Use Arrowhead Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ARWR a good stock to buy right now?
+
The case for Arrowhead Pharmaceuticals right now is REDEMPLO (plozasiran) launch and label expansion, with revenue (fy2025, ended sept 2025) at ~$829M. If you believe that thesis holds, ARWR is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Arrowhead Pharmaceuticals do?
+
Arrowhead Pharmaceuticals is a biopharmaceutical company built around RNA interference (RNAi), using its TRiM (Targeted RNAi Molecule) platform to design small interfering RNA (siR
What are the main risks of ARWR?
+
Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. The commercial uptake of REDEMPLO in the small FCS population is unproven, and broader label expansion depends on clinical and regulatory outcomes that can fail or slip. Competition in RNAi and lipid-lowering is intense from larger, better-capitalized rivals. Clinical trial setbacks, safety findings, regulatory delays, and partner decisions (including a partner pausing or returning a program) could all materially affect the stock, which is volatile like most clinical-stage biotech.
What does Arrowhead Pharmaceuticals do?
+
Arrowhead develops RNA interference (RNAi) medicines using small interfering RNA (siRNA) to silence disease-causing genes. Its TRiM platform delivers these drugs to the liver and increasingly to other tissues, targeting cardiometabolic, rare, pulmonary, and muscle diseases.
Is ARWR profitable?
+
Arrowhead reports profits only in quarters with large partner milestone payments and posts operating losses otherwise. As of JULY 2026 its revenue is lumpy and deal-driven rather than coming from steady product sales, so it is not consistently profitable.
What is plozasiran (REDEMPLO)?
+
Plozasiran, marketed as REDEMPLO, is Arrowhead's lead siRNA drug that targets APOC3 to lower triglycerides. It won FDA approval in November 2025 for familial chylomicronemia syndrome (FCS) and has also been approved in China, Canada, Australia, and the EU.
What is the Sarepta partnership?
+
In late 2024, Arrowhead signed a global license and collaboration with Sarepta Therapeutics covering multiple clinical and preclinical siRNA programs. It carried roughly ~$825M in upfront value (about ~$500M cash plus ~$325M equity) and has triggered further nine-figure milestone payments.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ARWR; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.